Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437946 | 0.94 | THRA (0.58) | THRATHRBSLC13A5MAPK14FFAR4 | |
| SCHEMBL23972417 | 0.91 | NR1H2 (0.53) | THRATHRBSLC13A5MMENR1H2 | |
| SCHEMBL4441015 | 0.89 | FFAR1 (0.54) | THRATHRBSLC13A5MAPK14FFAR4 | |
| SCHEMBL23296153 | 0.87 | SLC13A5 (0.56) | THRATHRBSLC13A5MAPK14FFAR4 | |
| SCHEMBL5126507 | 0.87 | RXRA (0.53) | THRATHRBSLC13A5FFAR4FFAR1 | |
| SCHEMBL5057604 | 0.86 | PSEN1 (0.54) | THRATHRBFFAR4FFAR1NR1H2 | |
| SCHEMBL5129224 | 0.85 | FFAR4 (0.50) | THRATHRBSLC13A5FFAR4FFAR1 | |
| SCHEMBL4441221 | 0.84 | MRGPRX4 (0.56) | THRATHRBFFAR4FFAR1MRGPRX4 | |
| SCHEMBL5122441 | 0.84 | FFAR4 (0.52) | THRATHRBSLC13A5MAPK14FFAR4 | |
| SCHEMBL761677 | 0.84 | MAPK14 (0.54) | THRATHRBSLC13A5MAPK14FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121591-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008109697-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PPARA, PPARG, PPARD | THRA 126/4885THRB 130/4885SLC13A5 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.